KVUE
NYSEKenvue Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 12 recent filings. 11 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Smith Jeffrey C Director | Grant / award | 1.41K | — | — | 2026-06-29 |
ALLISON RICHARD E JR Director | Grant / award | 1.41K | — | — | 2026-06-29 |
Howlett Heather CFO & CAO | Sell (open market) | 3.7K | $18.11 | $66,988.50 | 2026-06-10 |
Smith Jeffrey C Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
Hofstetter Sarah Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
HOLDEN BETSY D Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
MERLO LARRY J Director | Grant / award | 16.04K | $17.46 | $279,988.56 | 2026-05-21 |
PRABHU VASANT M Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
Sneed Michael E Director | Grant / award | 10.31K | $17.46 | $179,995.14 | 2026-05-21 |
Curado Gomes de Lemos Leonardo Group President LATAM | Option exercise | 24.25K | $0.00 | — | 2026-05-01 |
Curado Gomes de Lemos Leonardo Group President LATAM | Tax withholding | 7.14K | $17.43 | $124,467.63 | 2026-05-01 |
Curado Gomes de Lemos Leonardo Group President LATAM | Option exercise | 24.25K | $0.00 | — | 2026-05-01 |
Source: SEC EDGAR Forms 4/4A (CIK 1944048). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$JNJ $KVUE Rut Ro lol 😂 🙈 breaking news Talcum Powder PSC Says It Intends to Seek Reinstatement of Specific Causation Experts for Bellwether Cases in the Talc MDL
$JNJ $KVUE In the past year alone, juries have awarded a $1.5 billion verdict in Baltimore, a $966 million verdict in Los Angeles later reduced to $16 million, a $40 million ovarian cancer verdict in Los Angeles, a $32 million mesothelioma verdict in Los Angeles, and a $65.5 million mesothelioma verdict in Minnesota—all finding that J&J's talccausing the plaintiffs' cancers.
$JNJ $KVUE Shake n Bake Junk n Junk MDL talc trials start August 3rd in NJ 🤣🙈
$KVUE Coincedence? KVUE the maker of immodium, and DPZ the maker of COOKED products, both crapping out after the scare of cyclospora might be overdone.
$KVUE They make immodium. Seems like the 19's are a cheap shot for tomorrow under 10 cents
$JNJ $KVUE JNJ shares fall too, med tech earnings miss and huge Talc and Tylenol legal risks, that’s perfect medicine for them 🤣🙈
$KVUE moved to UTHR
$DJT $KVUE $KMB Federal appeals court revives Tylenol autism lawsuits against Kenvue, overturning prior dismissal Ruling reopens potential for thousands of previously dismissed Tylenol autism cases against Kenvue. Court decision could expose Kenvue to billions of dollars in Tylenol-related autism liability claims.
$KVUE back to 15 because of the banana republic legal system they installed.
Kenvue shares fell after Bloomberg reported that a U.S. federal appeals court revived lawsuits alleging the company concealed potential risks that Tylenol use during pregnancy could increase the likelihood of autism and other developmental disorders in children. A three-judge panel in New York ruled that the lower court abused its discretion by excluding testimony from three expert witnesses, sending the cases back for further proceedings, while agreeing that two other experts could remain excluded. The decision reverses a 2023 ruling that had prevented roughly 500 lawsuits from moving forward against Kenvue, the Johnson & Johnson consumer health spin-off. Plaintiffs claim the company failed to warn consumers about the alleged prenatal risks associated with the widely used over-the-counter pain reliever. $KVUE $JNJ
$KVUE is facing a new legal overhang. Shares dipped after a federal appeals court revived hundreds of lawsuits alleging Tylenol use during pregnancy may be linked to autism and ADHD risks. The company now faces renewed uncertainty around potential litigation costs and reputational impact. For investors, the key focus will be whether this becomes a material financial liability or remains a manageable legal headline.
RECAP 7/13 Chatter: $KVUE $KMB - Tylenol Autism suit revived RECAP 7/13 +Pos Comments: $CEPL + BWS Financial $QTTB + Wells Fargo Live Breaking trading news www.openoutcrier.com
Latest news
VOYA Stock Hits Record High, Tops $100 For The First Time Ever – Report Says Voya Financial Has Been ‘Fielding’ Takeover Interest
UBS Adjusts Price Target on Kenvue to $20 From $18, Maintains Neutral Rating
4 Dividend Kings Are Crushing the S&P 500 in 2026 and Still Have Big Upside Potential
Sector Update: Healthcare Stocks Advance Late Afternoon
Sector Update: Healthcare Stocks Higher Monday Afternoon
KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits
Top Midday Stories: Trump Says US to Be Guardian of Hormuz Strait; Meta to Invest Over $50 Billion in Louisiana Data Center Expansion
Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says
Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says
Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.